£9m fundraising gives Avacta extra firepower for cancer pipeline - Share Talk

£9m fundraising gives Avacta extra firepower for cancer pipeline

Avacta Therapeutics plc (AIM: AVCT) has strengthened its balance sheet after completing an oversubscribed £9 million equity fundraising, with proceeds earmarked primarily for reducing outstanding convertible bond debt and supporting the continued development of its oncology pipeline.

The clinical-stage biotechnology company placed 12.79 million new ordinary shares at 70p each, raising gross proceeds of approximately £9 million. The issue price matched the previous day’s closing mid-market price, avoiding any discount to the market.

Management said the fundraising attracted strong support from institutional investors and existing shareholders, with a single cornerstone institutional investor providing the majority of the capital.

Chief executive Christina Coughlin said the placing further strengthens Avacta’s financial position while preserving shareholder value.

“This Placing enables Avacta to retain the value of our equity while further reinforcing our financial position by reducing the outstanding debt in the Convertible Bond,” she said.

The company believes its existing cash resources now provide sufficient funding to advance both of its clinical-stage cancer therapies through major upcoming development milestones, while also progressing its third-generation pre|CISION® programme into IND-enabling studies.

Investors are expected to focus on several near-term catalysts. Avacta anticipates initial clinical data from its second-generation candidate AVA6103 during the second half of 2026, while additional Phase 1 data from lead programme AVA6000 will be presented later this month at the BIO International Convention.

Management believes these studies have the potential to provide further clinical validation of the company’s proprietary pre|CISION® platform, which is designed to activate cancer treatments directly within tumour tissue while reducing systemic toxicity.

Alongside the fundraising, chief executive Christina Coughlin and non-executive director Mark Goldberg each subscribed for 32,142 new shares at the placing price, investing approximately £22,500 each.

Avacta also confirmed that partnering discussions remain ongoing with multiple potential counterparties across all three generations of its pre|CISION® technology platform.

The fundraising follows recent positive clinical updates for AVA6000, which has demonstrated encouraging efficacy signals and a favourable safety profile, including the removal of traditional lifetime dosing limits associated with conventional doxorubicin due to strong cardiac safety data.


Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned